MENU

Company news

ImmuneOnco will share data in two posters at 2022 Annual Meeting of American Association for Cancer Research(AACR)

Date:2022-03-28 Views:168

    On March 28, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cancer Research (AACR) hold in New Orleans from April 8 to 13. Two abstracts from ImmuneOnco were selected for poster presentation at the AACR 2022. These posters will summarize the progress of the company's early clinical and preclinical pipelines like IMM2902 .

Dr. Wenzhi Tian, founder, chairman and CEO of ImmuneOnco, said:

    "The data we present at AACR 2022 will provide insight into the targets related to our 3 pipelines and promising data to support further clinical development. These study data have played a critical role in guiding our clinical development program. We are excited to have the opportunity to share these data with our colleagues in the oncology field.


About IMM2902

    IMM2902 is a new-generation bispecific drug candidate with global proprietary intellectual property rights, developed based on ImmuneOnco "mAb-Trap" technical platform. IMM2902 targets immune regulatory target CD47 and HER2, to inhibit tumor cell growth by accelerating the endocytosis and degradation of HER2, and to disinhibit and enhance the phagocytosis of macrophages against tumor cells by blocking the "don't eat me" signal mediated by CD47-SIRPα and activating the "eat me" signal mediated by Ig1Fc-FcγR. By the phagocytosis, processed tumor antigen was presented to T cells thereby exerting a powerful effect of tumor immunotherapy. IMM2902 is expected to be used mainly for HER2-expressing advanced solid tumors such as breast cancer, stomach cancer and lung cancer.